Blog
Health Reform: The Future for Drug (Non-)Price (Non-)Controls?
By Pharma & Healthcare Dimensions |
There’s more brewing in US health reform than ever. Is this good or bad for the world of pharma? ...
Read More Departing FDA Commissioners: Do Their Initiatives Continue?
By Pharma & Healthcare Dimensions |
Several clients have asked what Commissioner Gottlieb’s departure will mean – to their own industries and other FDA constituencies. To ...
Read More Pipeline Drugs: Another Victim of Rx Price Reforms
By Pharma & Healthcare Dimensions |
The drug pipeline is filled with high-priced, high-impact cures. Drug price reforms might kill them – is there any cure ...
Read More Opioids: PS on drugmaker liability
By Pharma & Healthcare Dimensions |
I recently posted some thoughts on the dilemma drugmakers face in balancing their reporting obligations to FDA against their general ...
Read More - « Previous
- 1
- 2
- 3
- Next »